Racura Oncology (ASX:RAC) announced the dosing of the third patient in its CPACS Phase 1 clinical trial, marking the completion of the initial dose cohort.
The latest treatment, administered at Queen Mary Hospital in Hong Kong under Principal Investigator Dr Roland Ching-Yu Leung, follows two earlier successful treatments at the Southside Cancer Care Centre.
To date, the study has observed no dose-limiting toxicities or adverse events, such as phlebitis, at the current 40mg/m2 dosage of RC220.
The completion of this first cohort triggers a formal review by the Safety Review Committee.
Pending clearance, the trial is scheduled to escalate to a dose level of 80mg/m2 in accordance with the updated protocol announced in February.
The expansion will broaden the trial’s geographical footprint, with recruitment continuing across multiple sites in Australia, Hong Kong, and South Korea.
The CPACS trial is an open-label study designed to evaluate the safety, tolerability, and pharmacokinetics of RC220 when combined with doxorubicin.
Beyond safety, investigators are monitoring clinical biomarkers to assess the drug’s cardioprotective mechanisms.
Following Stage 1, which involves up to 33 patients, the trial will transition into a Bayesian-designed Stage 2.
The next phase will assess an additional 20 patients to further refine the optimal dosage and identify preliminary signals of anticancer efficacy.